Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Bougnoux

Showing results (71-80 of 79) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 79 results.
British Journal of Cancer|July 9, 2009
All-oral combination of oral vinorelbine and capecitabine as first-line chemotherapy in HER2-negative metastatic breast cancer: an International Phase II TrialN Tubiana-Mathieu, P Bougnoux, D Becquart, et al.
British Journal of Cancer|June 5, 2003
Neoadjuvant docetaxel for operable breast cancer induces a high pathological response and breast-conservation rateS Amat, P Bougnoux, F Penault-Llorca, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|November 1, 1992
Disappearance of the in situ component: a criterion predictive of metastasis in breast cancer after local relapseB Chauvet, A Lemseffer, F Fetissoff, et al.
European Journal of Cancer (Oxford, England : 1990)|March 10, 2000
Low alpha-linolenic acid content of adipose breast tissue is associated with an increased risk of breast cancerV Klein, V Chajès, E Germain, et al.
Medical Oncology (Northwood, London, England)|August 20, 2005
Tumor parameters, clinical and pathological responses, medical management, and survival through time on 710 operable breast cancersC Abrial, M A Mouret-Reynier, S Amat, et al.
British Journal of Cancer|April 25, 2013
Everolimus as second- or third-line treatment of advanced endometrial cancer: ENDORAD, a phase II trial of GINECOI Ray-Coquard, L Favier, B Weber, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 28, 2006
A phase II study of a paclitaxel and oxaliplatin combination in platinum-sensitive recurrent advanced ovarian cancer patientsP Viens, T Petit, A Yovine, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 12, 2002
Multicentre phase II study of oxaliplatin as a single-agent in cisplatin/carboplatin +/- taxane-pretreated ovarian cancer patientsV Dieras, P Bougnoux, T Petit, et al.
Current Cancer Drug Targets|October 18, 2011
New alkyl-lipid blockers of SK3 channels reduce cancer cell migration and occurrence of metastasisA Girault, J-P Haelters, M Potier-Cartereau, et al.
Pageof 8

Showing results (71-80 of 79) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 79 results.
British Journal of Cancer|July 9, 2009
All-oral combination of oral vinorelbine and capecitabine as first-line chemotherapy in HER2-negative metastatic breast cancer: an International Phase II TrialN Tubiana-Mathieu, P Bougnoux, D Becquart, et al.
British Journal of Cancer|June 5, 2003
Neoadjuvant docetaxel for operable breast cancer induces a high pathological response and breast-conservation rateS Amat, P Bougnoux, F Penault-Llorca, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|November 1, 1992
Disappearance of the in situ component: a criterion predictive of metastasis in breast cancer after local relapseB Chauvet, A Lemseffer, F Fetissoff, et al.
European Journal of Cancer (Oxford, England : 1990)|March 10, 2000
Low alpha-linolenic acid content of adipose breast tissue is associated with an increased risk of breast cancerV Klein, V Chajès, E Germain, et al.
Medical Oncology (Northwood, London, England)|August 20, 2005
Tumor parameters, clinical and pathological responses, medical management, and survival through time on 710 operable breast cancersC Abrial, M A Mouret-Reynier, S Amat, et al.
British Journal of Cancer|April 25, 2013
Everolimus as second- or third-line treatment of advanced endometrial cancer: ENDORAD, a phase II trial of GINECOI Ray-Coquard, L Favier, B Weber, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 28, 2006
A phase II study of a paclitaxel and oxaliplatin combination in platinum-sensitive recurrent advanced ovarian cancer patientsP Viens, T Petit, A Yovine, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 12, 2002
Multicentre phase II study of oxaliplatin as a single-agent in cisplatin/carboplatin +/- taxane-pretreated ovarian cancer patientsV Dieras, P Bougnoux, T Petit, et al.
Current Cancer Drug Targets|October 18, 2011
New alkyl-lipid blockers of SK3 channels reduce cancer cell migration and occurrence of metastasisA Girault, J-P Haelters, M Potier-Cartereau, et al.
Pageof 8